Efficacy and safety of apremilast in patients with moderate‐to‐severe plaque psoriasis of the scalp: results up to 32 weeks from a randomized, phase III study
Van Voorhees A, Gold L, Lebwohl M, Strober B, Sofen H, Papp K, Bagel J, Zhang Z, Paris M, Wang Y. Efficacy and safety of apremilast in patients with moderate‐to‐severe plaque psoriasis of the scalp: results up to 32 weeks from a randomized, phase III study. British Journal Of Dermatology 2021, 185: 840-842. PMID: 33763874, PMCID: PMC8518877, DOI: 10.1111/bjd.20083.Peer-Reviewed Original Research